Association Between Vitamin D Status and Hypertriglyceridemic Waist Phenotype (HWP). by Hyelim Lee (11286822)

Subjects:

Distribution of Hypertriglyceridemic Waist Phenotype, abdominal obesity, and high triglyceride by serum vitamin D Status. by Hyelim Lee (11286822)

Subjects:

Characteristics of Study Participants. by Hyelim Lee (11286822)

Subjects:

Distribution of HWP by Criteria and Vitamin D Status (Two Groups). by Hyelim Lee (11286822)

Subjects:

Cohort characteristics. by Vincent Pey (21433304)

“…</p><p>Results</p><p>Upon initiation of CPB we observed a significant decrease in arterial whole blood redox potential (101.90 mV + /- 11.52 vs. 41.80 mV + /- 10,26; p < 0.0001). …”

Study selection criteria. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …”

Joinpoint regression trends in crude hospitalization and mortality rates of HPV-associated cancers in Mexico (2011–2019). by Juan Carlos Orengo (21546581)

Subjects:

Distribution of HPV-associated and attributable cancer deaths by type and sex, Mexico, 2011-2019. by Juan Carlos Orengo (21546581)

Subjects:

Hospitalizations for HPV-associated and HPV-attributable cancers by type and sex in Mexico (2011-2019): total numbers, averages, and crude rates per 100,000 population. by Juan Carlos Orengo (21546581)

Subjects:

Trends in age-standardized hospitalization rates by HPV-associated cancer type and sex (2011–2019): annual percentage change and average annual percentage change. by Juan Carlos Orengo (21546581)

Subjects:

Mortality for HPV-associated and HPV-attributable cancers by type and sex in Mexico (2011-2019): total numbers, averages, and crude rates per 100,000 population. by Juan Carlos Orengo (21546581)

Subjects:

Joinpoint regression trends in age-standardized hospitalization and mortality rates of HPV-associated cancers in Mexico (2011-2019). by Juan Carlos Orengo (21546581)

Subjects:

Trends in age-standardized mortality rates by HPV-associated cancer type and sex (2011–2019): annual percentage change and average annual percentage change. by Juan Carlos Orengo (21546581)

Subjects:

Distribution of HPV-associated and attributable cancer hospitalizations by type and sex, Mexico, 2011-2019. by Juan Carlos Orengo (21546581)

Subjects:

Age distribution and median age at hospitalization and death by HPV-associated cancer type and sex, Mexico, 2011–2019. by Juan Carlos Orengo (21546581)

Subjects:

Table 1_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.docx by Yi-Ming Ren (555968)

“…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …”

Table 5_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.docx by Yi-Ming Ren (555968)

“…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …”

Table 2_Causality of genetically determined serum metabolites on lower back pain or/and sciatica: a comprehensive Mendelian randomized study.docx by Yi-Ming Ren (555968)

“…Among them, 8 serum metabolites decreased risk of sciatica or/and lower back pain significantly (P < 0.05), and 14 serum metabolites increased risk of sciatica or/and lower back pain significantly (P < 0.05). …”